The first Ebola treatment drug in the research and development daily was approved by the FDA.

2020.10.15 Research and Development NEWS: Bayer copanlisib Unilever iNHL significantly extends patient PFS; innovative cell therapy is recognized by FDA Advanced Therapy for Regenerative Medicine; Wakix is approved by the FDA for new adaptations; Baxter Bio "calcium acetate tablets" are the first to pass a consistent evaluation; prevention migraine CGRP subject small molecule antagonists are expected to be approved next year... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original article) (Drug Development) Bayer copanlisib single anti-treatment iNHL significantly extended patients PFS14, Bayer announced the results of a Phase 3 clinical study CHRONOS-3, which evaluated the efficacy of the treatment of relapsed non-Hodgkin's lymphoma (iNHL).
study results show that the combination therapy has reached the main endpoint of significantly prolonged progress-free lifetime (PFS).
Drug Approval Regenerative And Antibody Combination Therapy became the first FDA-approved Ebola therapy the FDA announced that approved regenerative regenerative antibody cocktail therapy Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn, formerly listed under the name REGN-EB3) to treat Ebola virus infection in adults and children.
is the first FDA-approved drug to treat Ebola virus infection.
the only unregulated seizure d'onset d'onset drug! Wakix has been approved by the FDA as the only unregulated treatment for adult patients with narepsy, Harmony Biosciences announced.
Innovative Cell Therapy was announced by ORca Bio, FDA Advanced Therapy For Regenerative Medicine, and the FDA has awarded the company advanced therapeutics for cell therapy Orca-T Regenerative Medicine.
Orca-T is an allogeneic, high-precision cell therapy for blood cancer patients with hematopoietic stem cell transplantation.
prevention migraine CGRP recipient small molecule antagonist is expected to be approved next year Biohaven Pharmaceutical announced that the FDA has accepted the company's recent application for a new drug for the preventive treatment of migraines submitted by Rimegepant, and is expected to respond in the second quarter of next year.
Nurtec is a small molecule CGRP inhibitor.
Astrain/Amway potential "first-in-class" new drug clinical applications in China were accepted on the 14th, CDE website announced that AstraZeneca and Amway in China to declare a class 1 bio-new drug tezepelumab injection clinical trial applications, and received CDE acceptance.
, according to publicly available information, is a potential "first-in-class" new drug to be developed for the treatment of asthma, allergic dermatitis and other diseases.
and Nord once a week long-acting growth hormone declared clinically in China on the 15th, Novo Nordiak in China submitted sogroya (somapacitan) clinical application was accepted by CDE, a once-weekly subsulvy injection of long-acting human growth hormone, has been approved by the FDA in September 2020.
3 new class 1 drugs approved clinically from Haihe Pharmaceuticals, Regency Biology, Lingke Pharmaceuticals according to CDE public information, Hai and pharmaceutical PI3K alpha inhibitor CYH33 tablets, Regent BioCD137 activated antibody LVGN6051 monoclonal antibody injection and Lingco Pharmaceuticals LNK01001 capsule approved clinical, Lijin Biology and Lingke Pharmaceutical products are approved in China for the first time clinical.
another four-specific antibody clinical application was accepted by CDE latest publicity, The company submitted GNC-039 four-specific antibody injection clinical trial application was accepted.
september, the company's GNC-038 four-specific antibodies were approved clinically in China.
Anhui Baker Bio-produced Enqutah Binte Nofowe tablets into the administrative approval stage of the State Drug Administration official website shows that Anhui Baker Bio to imitate the 4 categories of reported Enqutah Pente Nofowe tablets into the administrative approval stage, sprinting the variety of domestic second.
2019 global sales of more than $2.8 billion as a drug used to treat AIDS.
Yuandong Bio "Grom bromine ammonium injection" will be the second approved 14th, Yuandong Bio 3 class generic drug Grombrom ammonium injection application to enter the "in the approval" stage, is expected to be formally approved in the near future, becoming the second domestic drug after Hengrui Pharmaceutical approved manufacturers.
high phosphorus blood medicine! The first of the "calcium acetate tablets" of the Bermeth creature passed the consistency evaluation on the 14th, and the calcium acetate tablets of the Bermeth creature passed the consistency evaluation, which was the first in China.
acetate tablets are a phosphorus binding agent, mainly used to prevent and treat end-stage renal disease hyperphosphateemia.
addition to Bermeth Bio, there are five manufacturers that are applying for or applying for a consistent evaluation of the drug.
7 months for the latest study! The results of the global Phase 3 trial of the PD-L1 inhibitor atezolizumab, a first-line treatment of advanced NSCLC, were published in the New England Journal of Medicine, and the survival of patients with high expression of PD-L1 was extended by 7.1 months compared to standard platinum chemotherapy.
.